Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma(LA HNSCC)
Multimodal management for Perioperative Analgesia in Otolaryngology ? Head and Neck Free Flap Reconstructive Surgery: A Prospective Study
Study Type: Treatment
Phase: N/A
NCTID: NCT04246697
Principal Investigator:
Yelizaveta Shnayder
Implementing the NYU Electronic Patient Visit Assessment ePVA for Head and Neck Cancer In Rural and Urban Populations
Study Type: Supportive Care
Phase: N/A
NCTID: NCT06030011
Principal Investigator:
Chris Lominska
A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig MEDI5752 as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy eVOLVE-HNSCC
TEMPUS PHOENIX HNSCC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Head Neck Squamous Cell Carcinoma HNSCC
Study Type: Other
Phase: N/A
NCTID: NCT06163534
Principal Investigator:
Prakash Neupane
Phase I/Ib Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer
Study Type: Treatment
Phase: I
NCTID: NCT05172245
Principal Investigator:
Chris Lominska
An Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma HNSCC
Phase III Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination with Cetuximab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor.
Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Platinum Refractory Disease.
Study Type: Treatment
Phase: III
NCTID: NCT06589804
Principal Investigator:
Prakash Neupane